Chief Accounting Officer
Fulcrum Therapeutics, Inc. (FULC)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Alan Musso is recorded as CFO and Chief Accounting Officer at Fulcrum Therapeutics, Inc. (FULC). Fulcrum Therapeutics, Inc. reported in an 8-K filed August 10, 2026 that Alan Musso was appointed principal accounting officer, effective August 7, 2026. The proxy statement of Fulcrum Therapeutics, Inc. reports total compensation of $1,807,125 for Alan Musso in fiscal 2025, including a base salary of $478,100. Disclosed compensation is on record for 3 fiscal years. Alan Musso has spoken on 8 earnings calls across 1 company, most recently for Fulcrum Therapeutics, Inc. on April 27, 2026.
“on August 9, 2026, Fulcrum's Board of Directors appointed Alan Musso, Fulcrum's chief financial officer and principal financial officer, as principal accounting officer, effective August 7, 2026, upon Mr. Tourangeau's departure.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2026-08-07–present
Recorded roles and call appearances connecting this person to public companies.
CFO, Chief Accounting Officer
2026-08-07–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | $478,100 | $1,807,125 |
| 2024 | Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | $457,500 | $1,251,760 |
| 2023 | Fulcrum Therapeutics, Inc. (FULC) | Chief Financial Officer | $180,682 | $1,879,833 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
